Th e infl uence of genetics in the etiology of infl ammatory bowel disease (IBD) was initially demonstrated by epidemiological data, including diff erences in prevalence among diff erent ethnic groups, familial aggregation of IBD, concordance in twins, and association with genetic syndromes. Th ese early observations paved the way to molecular genetics in IBD, and culminated in the identifi cation of nucleotide-binding oligomerization domain containing 2 (NOD2) gene as an IBD risk gene in 2001. As in other complex diseases, the advent of Genome Wide Association studies has dramatically improved the resolution of the IBD genome and our understanding of the pathogenesis of IBD. However, the complexity of the genetic puzzle in IBD seems more pronounced today than ever previously. In total, 163 risk genes/loci have been identifi ed, and the corresponding number of possible causal variants is challenging. Th e great majority of these loci are associated with both Crohn's disease and ulcerative colitis, suggesting that nearly all of the biological mechanisms involved in one disease play some role in the other. Interestingly, a large proportion of the IBD risk loci are also shared with other immune-mediated diseases, primary immunodefi ciencies and mycobacterial diseases.
Introduction
Th ere has been great progress within the fi eld of molecular genetics in infl ammatory bowel disease (IBD). Th e early epidemiological fi ndings, and especially the observed concordance within twin pairs, were the major triggers that commenced the successful era of molecular genetics in IBD. Even today, these key observations can bring important pieces to our understanding of the pathogenesis of IBD.
Genetic epidemiology Ethnic diff erences
IBD has been associated with considerable geographic and ethnic diff erences in incidence and prevalence [1] . Generally, the incidence of both Crohn's disease (CD) and ulcerative colitis (UC) has gradually increased since the Second World War, especially in northern Europe and North America, where the highest incidence rates have been reported [2] [3] [4] [5] [6] [7] . In several areas with traditionally low occurrence of IBD, such as Asia and Africa, increasing fi gures have been reported in more recent years [8] [9] [10] [11] . Although historical diff erences could be infl uenced by a number of factors, including diff erent types of biases, these shift s in the risk of developing IBD within limited period of times can barely be explained by changes in the genome, but rather provide evidence for the importance of exposure to environmental factors in the disease pathogenesis. On the other hand, the higher risk of CD in Jews, and especially in Ashkenazi Jews, seem to persist irrespective of geographic location or time period [12] [13] [14] [15] [16] , suggesting that there actually might be ethnic diff erences in the genetic predisposition to IBD.
are disease specifi c and some variants are common to both UC and CD, whereby environmental factors might infl uence disease phenotype [33, 34] . In recent years, molecular genetics has confi rmed that certain genetic variants are shared by CD and UC and other variants are disease-specifi c [35] . Th e recent reported associations between methylation of specifi c regions of the genome and CD [36] may indicate that environmental factors could infl uence disease phenotype in IBD by epigenetic modifi cations of the genome.
Risk for relatives
Th e greatest risk for developing IBD is having a relative with the disease [22, 25, 26] . On the whole, the estimated relative risk to a sibling of a patient with CD is , and the corresponding fi gures are 7-17 for UC [37] . However, from a clinical perspective patients ask for the absolute risk and not the relative risk of IBD in relatives, especially off spring. Th ere are limited studies addressing this clinically relevant question, and quoted absolute risks diff er between the studies. Overall, a lifetime risk of developing IBD for fi rst-degree relatives of a CD patient is 4.8-5.2% for non-Jews and 7.8% for Jews [14, 26, 32] . Th e corresponding fi gures for fi rst-degree relatives of a patient with UC are 1.6% for non-Jews and 5.2% for Jews [14] . Similarly, the age-corrected risk for off spring of a CD patient developing IBD is reported to be 0-10.4% in non-Jews and 7.4-15.8% in Jews. Th e equivalent estimates for off spring of a patient with UC are 11% and 2.9-7.4%, respectively [14, 26, 32] .
Th e risk of IBD in an off spring increases dramatically if both parents suff er from IBD. Case series have estimated the risk of IBD in the off spring to be 33-52%, depending on follow up [38, 39] .
Phenotypic similarities within families with IBD
IBD has traditionally been categorized as CD, UC, or IBD unclassifi ed [40, 41] . However, there are great heterogeneities within the three diff erent diagnoses, suggesting the existence of subgroups. Epidemiological studies from the mid-1990s of familial IBD suggest that there could be a genetic basis for these diff erent subgroups. In general, a high degree of clinical similarities of IBD has been observed within multiplex families, and data are especially striking for CD. Several groups have reported concordance for location of disease and some also for disease behavior, age at diagnosis, extraintestinal manifestations and number of bowel resections [26, 31, [42] [43] [44] .
Less is known about concordance within families with multiply aff ected members with UC. Some agreement in disease extent has been reported [42, 45] , although the observed concordance rates were higher within families with CD, which supports a smaller contribution of genetics in UC than in CD. It cannot be ruled out that the observed concordance in disease characteristics within families with IBD is an eff ect of shared environment within the families, rather than of genetic predisposition. In contrast to the fi ndings in families with IBD, no similarities were identifi ed in a study of married couples with CD [39] .
Familial and sporadic IBD
Based on the fi ndings in family studies, it has even been proposed that familial IBD could be a diff erent entity than sporadic disease. However, the evidence for phenotypic diff erences between these two groups is sparse, and data are inconsistent. An earlier age at onset for familial cases of IBD than for patients without any family history of IBD is probably the most robust observation [14, 28, 43, 46] . Predominance of female cases [21, 43, 44] and predominant transmission from mother to child has also been described, especially in CD [21, 43, 44, 47, 48] . Based on these fi ndings, a female sex-specifi c epigenetic inheritance pattern for CD has been proposed, which could contribute to the familyspecifi c risk in CD [48] . Beyond younger age at diagnosis and predominance of female cases, diff erences in disease location, behavior, extraintestinal manifestations, and disease severity between familial and sporadic disease have been proposed. However, interpretation of the data is diffi cult, since defi nitions diff er between the studies, univariate analyses have oft en been employed and associations between diff erent clinical characteristics exist [14, 33, 43, 44, 49, 50] .
Twin studies
In 1988 Tysk et al published the fi rst unbiased study showing a higher concordance rate in monozygotic twin pairs than in dizygotic twin pairs with CD, refl ecting the infl uence of genetics in the disease pathogenesis [51] . Since then, data on twins with IBD have been reported from the United Kingdom, Denmark, and Germany [52] [53] [54] [55] [56] . Th e design of the studies diff ers between countries, with the Scandinavian studies being based on the national twin registry in each country [51, 52] . In contrast, the British and German studies were set up by calls for twins with IBD using advertisements and newsletters distributed to members of the national patient organizations and physicians within each country [53] [54] [55] [56] . Since the pair concordance rate, simply refl ecting the proportion of concordant pairs, varies with the thoroughness of ascertainment, the proband concordance should be used for comparisons between diff erent studies. In the pivotal study by Tysk et al proband concordance rates of 58% and 4% in monozygotic and dizygotic twins with CD, respectively, were observed, refl ecting the pronounced genetic predisposition [51] . Th e corresponding fi gures for twins with UC were 6% and 0%, respectively. Orholm et al later confi rmed these fi ndings in the Danish cohort, where proband concordance rates of 58% and 0% were observed in monozygotic and dizygotic twins with CD, respectively [52] . Similarly, the corresponding rates in twins with UC were 18% and 4%, respectively. Follow ups of the two Scandinavian cohorts, extending the observation period in previous healthy twin siblings, had only marginal eff ects on the concordance rates, since just a few additional twins had been diagnosed during the extended observation ( Table 2) .
Th e population-based data from the Scandinavian twin registries are supported by the German and British twin studies [53] [54] [55] [56] . Overall the concordance is higher in monozygotic than in dizygotic pairs, and the diff erence is more pronounced in CD than in UC [60] , although the British study does not include any information on proband concordance rates. Recently, the extraordinarily high concordances in monozygotic twins have been questioned. Th e very short observation periods between the year of birth in national twin cohorts and the year of study might have biased the inclusion towards twins with early onset disease and possibly with a more aggressive disease course, disease phenotypes that could be associated with a more pronounced genetic predisposition [58] . In contrast to some of the previous family studies in IBD, none of the original twin studies have standardized their fi ndings according to age. Similarly, the follow-ups of the Scandinavian cohorts have studied twin pairs included in the original publications only, not extending their analyses to potential new twin pairs within the total background population in each country. By rerunning the Swedish hospital discharge register with the Swedish twin registry and restricting the analyses to twins born during the original studied period, that is, 1886-1958, the proband concordance rates in monozygotic and dizygotic twins with CD were corrected to 38% and 2%, respectively [58] . Th e corresponding fi gures for twins with UC were 15% and 8%, respectively. Reported heritability, providing an estimate of the relative contribution of genetics to disease etiology, is very high, especially in CD, and within the same range as other complex diseases with a pronounced genetic contribution. However, the fi gures needs to be interpreted with caution, since the methods for calculating the heritability vary with the studies, and the confi dence intervals when reported are wide. A higher relative risk for concordant disease has also been observed in dizygotic twins than in ordinary siblings [61] . Th is would point towards the contribution of shared internal intrauterine factors and/or shared external childhood environment, although the conclusion should be treated with some caution, since the results are based on small numbers and a less robust method.
Concordance in clinical characteristics has also been observed within twin pairs where both twins are aff ected by IBD. Th is was fi rst reported in the follow up of the original Swedish twin study [57] . Using the Vienna classifi cation [62] , a remarkable phenotypic similarity was observed statistically within twin pairs, considering age at diagnosis, location of the disease, and possible progress in disease location, in spite of the limited number of concordant monozygotic twins with CD. Although the similarity in disease behavior, defi ned as non-stricturing non-penetrating disease, stricturing disease or penetrating disease, was of borderline signifi cance only, concordance in disease behavior has been confi rmed more recently in the combined Swedish-Danish twin cohort [63] . Th e observation of concordance in disease behavior also includes the entity perianal disease. Beyond the similarity in clinical characteristics at diagnosis of CD, phenotypic concordance in disease behavior and location has also been reported longitudinally 10 years aft er diagnosis. Th ese fi ndings point towards a pronounced genetic impact on clinical characteristics. However, comparison with concordant dizygotic twin pairs with CD could not be performed, due to low numbers. Th us, it cannot be ruled out that the phenotypic similarity within monozygotic twin pairs concordant for CD is due to shared internal intrauterine factors and/or shared external childhood environment rather than to genetic predisposition. Also still to be explored is the possible infl uence of disease tolerance, that is, diff erences in susceptibility to tissue damage, in contrast to disease resistance [64] .
In contrast to the high degree of similarity within pairs with CD, phenotypic concordance has been observed for age at diagnosis and symptomatic onset only in monozygotic twins where both twins are aff ected by UC [57, 59, 63] .
Associated syndromes and diseases with well recognized genetic susceptibility
Early observed associations of IBD with genetically determined syndromes, including Turner syndrome [65] , HermanskyPudlak syndrome [66] , glycogen storage disease Ib [67] , cystic fi brosis [68] , and pachydermoperiostosis [69] , provided additional epidemiological evidence for a role of genetics in IBD. An increased prevalence of IBD has also been observed in other infl ammatory disorders with strong evidence of genetic susceptibility, like ankylosing spondylitis [70] , psoriasis [71] , multiple sclerosis [72] , and celiac disease [73] . Recent molecular studies have also revealed shared genetic architecture between several chronic immunemediated diseases and additional data are awaited [74] .
Molecular genetics
Genetics plays an important role in susceptibility to a wide variety of complex human diseases (diseases regulated by many genes as well as the environment). Almost 100 years ago, R.A. Fischer and others reconciled the discrete Mendelian inheritance of individual genes with the continuous distribution of complex heritable traits. While familiar clustering is observed for several of these diseases, only a few diseases seem to strictly follow Mendel's law of inheritance. Instead, the majority of diseases involve the action of many genes (as well as non-genetic or environmental factors). Th ousands of mutations in single genes have been found to cause 'Mendelian disorders' , while attempts to fi nd single causative genes for complex diseases have been relatively unsuccessful. Th e mode of inheritance clearly demonstrates that CD and UC are not simple monogenetic Mendelian disorders but genetically complex diseases. Th e observed concordance in twin studies and families with IBD were the major triggers leading to the application of molecular genetic approaches in IBD.
Early linkage studies
Early association studies in the 1980s, using functional candidate genes, focused mainly on the HLA genes and progressed rather slowly, showing fairly disappointing results [75] . Subsequent genome wide scanning based on linkage studies, using microsatellite markers of tri-or tetranucleotide repeats, identifi ed over-proportional shared regions of the chromosomes in aff ected relative pairs. In 1996, the fi rst two genome scans using this strategy were published [76, 77] . Th e fi rst region of replicated linkage, meeting the Lander and Kruglyak criteria for signifi cant linkage [78] , was located on chromosome 16 (IBD1) [37] . Subsequent studies identifi ed and replicated areas of signifi cant linkage on additional chromosomes subsequently designated as IBD1-9 [37, 79] . Some disease loci were disease specifi c, like IBD1 showing linkage in CD only, and others showed association with both CD and UC.
Nucleotide-binding oligomerization domain containing 2 (NOD2) gene
In 2001, two independent groups identifi ed the fi rst CD susceptibility gene, NOD2 gene within the IBD 1 locus [80, 81] .
Hugo et al described the identifi cation of NOD2 using positional cloning strategy, while Ogura et al used positional plus functional candidate gene approach based on its location within the IBD1 locus and structural homology with NOD1. Th e NOD2 consists of two amino-terminal caspase recruitment domains (CARDs), a centrally located nucleotide binding domain and multiple leucine rich repeats (LRRs) at its carboxyterminal end. Hugo et al found independent associations with CD for three diff erent polymorphisms in NOD2, all three located in or near the LRR region [80] . Th ese three variants comprise the frameshift mutation (Leu1007fi nsC), which causes a truncated protein transcript, and two nonsynonymous polymorphisms (Arg702Trp and Gly908Arg).
Th e identifi cation of NOD2 was a major breakthrough and the independent associations between the three single nucleotide polymorphisms (SNPs) and CD have been widely replicated. Th e great majority of studies suggest a gene dosing eff ect. Carriage of one copy of the risk alleles confers to a modest increased risk of developing CD, i.e. 2-to 4-fold. However, having two copies, homozygote or combine heterozygote, is associated with a 20-to 40-fold increased risk. Th e prevalence of the three major coding polymorphisms varies throughout the world, both in the healthy background population and in individuals aff ected by CD [82, 83] . Highest prevalence rates have been reported from some parts of Europe and USA, with up to 40% of patients with CD carrying at least one of the polymorphisms. On the other hand, lower mutation rates have been reported from Northern Europe, including Scandinavia and Scotland, and NOD2 mutations seem to be almost absent in Asian countries like Japan, Korea and China [79, 83] .
Genome-wide association studies
Th e principal insight learned from the early genetic studies in IBD was that there is no single gene (nor even a very small number) but rather a large number of involved genes. Linkage studies (previously described), lose power rapidly with decreasing eff ect of the associated genetic variant. So if the genetic basis of IBD consists of dozens or hundreds of small eff ects, then linkage would never have the power to discover them. Genome-wide association studies (GWAS), where one compares the allele frequency of a particular variant between unrelated cases and controls, was the next step to unravel the genetic architecture of complex diseases like IBD. GWAS have successfully been used to discover loci with tiny eff ects, thereby confi rming the increasing suspicion that individual common risk alleles generally show very weak eff ects on disease risk [84] .
While the index GWAS identifi ed loci conferring (in complex disease genetics terms) larger eff ect sizes they were, in retrospect, underpowered to detect loci that confer an odds ratio (OR) of disease of <1.2. Reliable identifi cation of such loci requires analysis of substantially larger sample sets. In order to gain power to index GWAS, individual scans were combined into a GWAS meta-analysis. Th ese studies, which typically consist of many thousand individuals, confi rmed the suspicion that a large number of additional common alleles of small eff ect were to be identifi ed.
GWAS for IBD
During the last years, IBD has seen tremendous success in the identifi cation of disease susceptibility alleles. Large GWAS meta-analyses of CD and UC, that followed a few independent GWAS, have dramatically increased our knowledge of IBD genetic risk factors. Presently, 163 susceptibility loci are described in the published literature [35] .
Historically, only 6 months aft er the fi rst GWA study was published, Yamazaki and colleagues published the fi rst association study for CD. Th is study only included 72,738 SNPs and identifi ed several associated SNPs in the TNFSF15 gene [85] . One year later, a larger association study was published for CD. Besides the previously known risk locus NOD2, this study identifi ed CD-risk variants in the interleukin 23 receptor (IL23R) gene. Th is was further replicated in cohorts of both CD and UC patients that confi rmed ILR23R to be a gene common for both IBD subphenotypes [86] . Th e fi rst large-scale association study specifi cally targeting UC was published in 2008 [87] . Th is study identifi ed three loci associated to UC, namely the major histocompatibility complex (MHC) region (which confi rmed previous fi ndings), the gene encoding the extracellular matrix protein 1 (ECM1), expressed in the small and large intestine and involved in nuclear factor (NF)-κB activation [88] , and the macrophage stimulating gene MST1, previously shown to be associated to both CD and UC [89] .
Studying early-onset presentations of complex disease is appealing to geneticists because of the expectation that these eff orts have a higher chance of identifying novel risk variants that have not been identifi ed in adult-onset studies. Early onset IBD shows more extensive disease at onset and rapid progress. IBD presents during childhood or adolescence in 15-20% of patients [90] . Two recent GWAS carried out exclusively in this age group have demonstrated genetic similarities between early-and adult-onset IBD [91, 92] . In the fi rst study, which was a subset of the second GWA study, Kughasan et al replicated several known loci from previous adult-onset studies (NOD3, IL23R, HLA, TNFSF15) and identifi ed two novel diseaseassociated loci, 20q13 and 21q22 [92] . Th e authors were not able to pinpoint the causal gene in the 20q13 region but considered TNFRSF6B to be the most compelling candidate based on the critical role of specifi c polymorphisms within genes involved in the TNF pathway in the pathogenesis of IBD. Th e 21q22 signal resides in a small region of LD that harbors no genes, with the nearest gene being PSMG1. Later, a Canadian study for early-onset CD replicated the 20q13 locus but not the 21q22 fi nding [93] . A follow-up early-onset IBD GWAS was published by the same group and identifi ed fi ve new loci associated with early-onset IBD, including 16p11 close to the cytokine gene IL27 [91] . Th is study also replicated 23 of 32 loci previously implicated in adult-onset CD and 8 of 17 loci implicated in adult-onset UC, which highlights the close pathogenetic relationship between early-and adult-onset IBD.
In 2011, GWAS had identifi ed 41 loci signifi cantly associated to CD [87] . When combining previous GWAS into a meta-analysis, including a total of 22,027 CD cases and 29,082 controls, another 30 signifi cantly associated loci were found, which adds up to a total of 71 loci, explaining 23.3% of the estimated heritability for CD [94] . Following in silico analyses and manual curation a number of positional candidate genes were identifi ed as being of interest, including SMAD3, ERAP2,  IL10, IL2RA, TYK2, FUT2, DNMT3A, DENND1B, BACH2 and TAGAP [94] . A few independent studies had at the same time identifi ed 18 loci signifi cantly associated to UC. Th is was followed by a meta-analysis including previous independent studies, including a total of 16,000 cases with UC and 32,000 controls. In total, 29 additional loci for UC were identifi ed from this eff ort, increasing the number of known UC loci to 47, with an estimated heritability explained of 16%. Aft er annotating associated regions using a gene relationship across implicated loci pathway analysis, expression quantitative trait loci data and correlations with non-synonymous SNPs, several candidate genes, including IL1R2, IL8RA-IL8RB, IL7R, IL12B, DAP, PRDM1, JAK2, IRF5, GNA12 and LSP1, were identifi ed, providing potentially important insights into disease pathogenesis [95] .
Only a year later, the International IBD Genetics Consortium (IIBDGC) expanded the breadth of these analyses reporting one of the largest meta-analyses ever performed, based on 75,000 IBD (UC and CD) cases and controls including data from 15 diff erent GWAS for UC and CD. Th is study also included additional typing on the immunochip, an array specifi cally designed to capture variation at 200 known risk loci for 12 common autoimmune diseases [35] . From this study, 71 new causative regions were identifi ed, which brought the total number of independent IBD risk loci to 163, far more than reported for any other complex disease. For the 163 confi rmed IBD loci, 110 appear to be relevant to both CD and UC, 23 show risk eff ects that are UC-specifi c and the remaining 30 are CD-only loci. Th e individual gene and causal variant are yet to be explored in many of these loci and even less is known about their functional implications. Fig. 1 summarizes a number of the confi rmed common and disease specifi c loci, represented by lead gene name, according to pathway. Interestingly, 43 of these 53 disease specifi c loci show the same direction of eff ect in both CD and UC, suggesting that nearly all of the biological mechanisms involved in one disease play some role in the other. One intriguing exception is NOD2, which still represents the strongest causal gene in CD but shows signifi cant protective eff ects in UC, an observation that may refl ect biological diff erences between the two diseases.
Many IBD-associated genes are involved in T-cell diff erentiation (for example cytokines IL21, IL10, IFNG. and cytokine receptor IL7R). Some of them are more specifi cally associated with the IL23R pathway (IL23R, JAK2, STAT3, IL12B, and PTPN2), involved in the maintenance of T H 17 cells and in several other diseases. T H 17 cells are thought to coordinate defence against specifi c pathogens and mediate infl ammation [96] , and the original identifi cation of IL23R as an IBD risk factor shattered the paradigm that CD and UC were primarily T H 1 and T H 2 -mediated diseases, respectively [86] . TNF-signaling genes (TNFRSF9, TNFRSF14, and TNFSF15) are also well represented among IBD genes. Th ese genes encode proteins with various immune eff ects including systemic infl ammation and activation of infl ammatory transcription factor NF-κB. As predicted from Cellular innate immunity NOD2 IRGM ATG16 LRRK2 Immune-mediated  IL2RA  IL18RAP  IL27  PTPN22  CCR6  ERAP2  CCL2/CCL7  TNFSF11  BACH2  ITLN1  TAGAP  VAMP3   CD   Other   GCKR  THADA  SP140  PRDX5  ZPF36L1  ZMIZ1  CPEB4  FADS1  TAGAP  DENNDIB  DNMT3A  MUC1/SCAMP3   Other   ORMDL3  RTEL1  PTGER4  KIF21B  NKX2-3  CREM  CDKAL1  STAT3  ZNF365  PSMG1   IBD   HLA   DRB103   Immune-mediated   IL10  CARD9  MST1  REL  ICOSLG  IL1R2  YDJC  PRDM1  TNFSF15  SMAD3  PTPN2  TNFRSF6B   Th17   STAT3J  L23R  IL12B  AK2  FUT2  TYK2   UC   Epithelial  barrier   ECM1  HNF4A  CDH1  LAMB1  GNA12  Immune-mediated   IL8RA / IL8RB  IL2 / IL21  IFNY / IL26  IL7R  TNFRSF9  TNFRSF14  IRF5  LSP1 Th e additional typing on the immunochip, which is a custom-made chip that includes 200,000 SNPs relevant to multiple diff erent immune-mediated diseases including UC and CD, discovered that a large portion of IBD risk loci are shared with other complex immune-mediated diseases (particularly ankylosing spondylitis and psoriasis), primary immunodefi ciencies and mycobacterial disease, pointing to an essential role for host factors involved in defense against infection in IBD [35] . Th ese fi ndings point towards shared pathogenic mechanisms between 'distinct' diseases and confi rmed previous reported epidemiologic overlap between IBD and other immunemediated diseases [97] [98] [99] , and observed genetic overlap in GWA-based studies [100] [101] [102] [103] . However, the resolution of the immunochip study revealed that there is a high degree of complexity of this genetic architecture. Th e genetic overlap does not necessarily consist of a shared loci for which the same SNP or haplotype confer to increased risk for more than one immune-mediated disease. Instead, the same SNP or haplotype might confer to increased risk for one disease but may be protective for another, alternatively the overlap might be caused by diff erent haplotypes within the loci [104] . Th e associations with gene coding for proteins involved in autophagy and innate immunity point towards the importance of defective processing of intracellular bacteria in CD. Th e genetic overlap between CD and susceptibility to infection with Mycobacterium leprae is particularly intriguing. A total of seven out of eight susceptibility loci, including NOD2, IL23R, RIPK2 and TNFSF15, for infection with Mycobacterium leprae have also been associated with CD, although with genetic eff ects in diff erent directions for some of these associations. It is still to be explored whether this shared immunogenetic risk profi le underpins a true causative role for mycobacteria in CD, or rather represent the result of convergent evolutionary adaptations to several pathogens.
Future aspects
In spite of the dramatic progress within molecular genetics in recent years, some of the key epidemiological observations are still unanswered. Based on analyses of the DNA sequence, the observed high heritability in IBD is only partly understood. Future fi ne-mapping eff orts of identifi ed loci are awaited. At the present, a transition from GWAS-style date (which only studies a subset of common variation) to complete genome sequencing is enabled by the decreased cost of sequencing [105] . Sequencing has the potential to enable the wide spectrum of variation beyond the common alleles targeted by GWAS. Possible contributions of other molecular mechanisms of heritability, such as epigenetics, are still largely undiscovered and need to be explored. Similarly, the pronounced phenotypic similarities within multiplex families and especially within concordant monozygotic twin pairs with CD suggest that genetics also infl uences the phenotype of the disease. Patients with IBD have so far not benefi ted from the scientifi c progress within molecular genetics, but clinical applications are awaited. Up until now, it has been diffi cult to establish any fi rm genotype-phenotype associations beyond NOD2, but analyses addressing possible contribution of other loci based on data generated by typing on the immunochip are under way. Similarly, genetic models for predicting disease diagnosis, CD vs. UC, or even phenotypic subcategories of these two diagnoses are expected within the near future. Preliminary data also suggest that genetic analyses might be used for prediction models of treatment response in the future. Th e IIBDGC's study on the risk of colectomy in acute severe UC might be the most promising example, where an association between rs2403456 (11p15.3) and colectomy has been reported [106] . Future longitudinal studies with periodic measurements in subjects at high risk, that is siblings and off spring below or around the peak age of onset of IBD, as well of treatment naïve, newly diagnosed patients will probably become important tools to elucidate the genetic and environmental interactions underlying these archetypal complex diseases.
